Nobel Prize 2022: Three scientists jointly received the Nobel Prize in Chemistry for this achievement. Nobel Prize 2022: Three scientists jointly receive the Nobel Prize in Chemistry

New Delhi:

Caroline R. Bertozzi, Morten Medel and K. Barry Sharpless (Carolyn R Bertozzi, Morten Meldal and K Barry Sharpless) has been jointly honored with the Nobel Prize in Chemistry. All three have been awarded for their work on ‘Click Chemistry’. In fact, this work of his is very useful in the field of medical science including the treatment of deadly diseases like cancer. Bertozzi is from Stanford University in California, Sharpless is affiliated with Scripps Research in California and Meldl is from the University of Copenhagen in Denmark.

According to the website of the Royal Swedish Academy of Sciences in Stockholm, Sweden, “Barry Sharpless and Morten Meldl have been awarded the 2022 Nobel Prize in Chemistry because they brought chemistry into the era of functionalism and laid the foundations for click chemistry. The statement said .that they were given together with Caroline Bertozzi, who gave a new dimension to click chemistry and began using it to map cells.Her bioorthogonal responses have now been shown to be useful in cancer treatments.

What is Click Chemistry?
In click chemistry, chemists often try to recreate complex chemical molecules found in nature. It is also used in the field of medicine, among other fields. They try to target and block pathogenic factors in cells. The Nobel Prize website states that click chemistry and bioorthogonal reactions have brought chemistry into the era of functionalism, which is proving to be of great benefit to mankind.

Bertozzi’s discovery ends cancer thus
The area where Bertozzi’s work is focused is glycans on the surface of tumor cells, according to the Nobel website. His studies have shown that certain glycans appear to protect tumors from the body’s immune system. , because they shut down immune cells. To block this defense Mechanism of tumors, Bertozzi and his colleagues have created a new type of biological drug. They are joined by a glycan-specific antibody to enzymes, which break down glycans on the surface of tumor cells. This drug is now being tested in clinical trials in people with advanced cancer.